Author

J. E. Cummings

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

R. A. Slayden· 2 shared D. W. Beasley· 1 shared E. B. Whorton· 1 shared I. Macias-Perez· 1 shared J. E. Peel· 1 shared J. W. Peterson· 1 shared K. W. Slayden· 1 shared M. E. Hensel· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

R. A. Slayden

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model

W. S. Lawrence, J. E. Peel, R. Slayden, J. W. Peterson, W. B. Baze, M. E. Hensel, E. B. Whorton, D. W. Beasley, J. E. Cummings, I. Macias-Perez

This study evaluates telavancin's in vitro activity against B. anthracis and its protective efficacy in a rabbit inhalation anthrax model, showing 100% survival and effective bacterial clearance.

bioRxiv · Feb 13, 2023 · PreprintMicrobiology

TPR1, a novel rifampin derivative demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A Priority Pathogen F. tularensis

J. E. Cummings, K. W. Slayden, R. A. Slayden

This study evaluates the efficacy of TPR1, a rifampin derivative, against F. tularensis both alone and in combination with doxycycline, showing reduced bacterial burden and 100% survival in mice.

bioRxiv · Feb 12, 2021Microbiology

Profiling susceptibility of NIAID Category A and B priority and emerging pathogens to define strain panels for drug discovery and active drug classes

J. E. Cummings, Z. Abdo, R. A. Slayden

The paper assesses drug susceptibility of NIAID priority pathogens to standard of care drugs, identifies non-redundant strain panels, and classifies pharmacophores for drug discovery.

bioRxiv · Dec 4, 2020 · PreprintMicrobiology